BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 3, 2010
View Archived Issues
Phase I data support efficacy and safety of MGN-1703 in metastatic tumors
Read More
ICOVIR-7 is safe and active in refractory solid tumors
Read More
Modified-release prednisone at bedtime improves asthma control
Read More
WYE-103231 shows potent activity in thermoregulation and pain
Read More
Low mGluR5 binding/expression involved in pathophysiology of MDD
Read More
CRHR1 SNPs involved in anxiety improvement in GAD and MDD
Read More
Fluvastatin does not influence inflammation markers after stroke
Read More
Boehringer Ingelheim claims new FADK1 inhibitors
Read More
Lundbeck discovers new NPY Y5 receptor ligands
Read More
Bayer Schering Pharma claims new HIF-1 inhibitors
Read More
Roche claims new prostanoid DP2 receptor antagonists/partial agonists
Read More
Novo Nordisk to soon launch Victoza in Japan
Read More
Centocor Ortho Biotech acquires RespiVert
Read More
NICE releases initial decision on omalizumab use in children with asthma
Read More
FDA approves Prolia therapy for postmenopausal women with osteoporosis
Read More
Belgian FAMHP clears phase III Reolysin trial in head and neck cancers
Read More
Enrollment begins in phase III rifamycin trial in travelers' diarrhea
Read More
NanoViricides' antidengue agents demonstrate preclinical efficacy
Read More
FDA grants orphan drug status to THPB in Niemann Pick type C disease
Read More
FDA accepts Orexigen's Contrave NDA in obesity for filing
Read More
LLS and Onconova partner to develop ESTYBON in high-risk MDS
Read More
Final data reported of halted phase III idronoxil trial in ovarian cancer
Read More
Dosing complete in phase I trial of ND-0611 for Parkinson's disease
Read More
Lorus files IND for phase I trial of anticancer agent LOR-253
Read More
Sunesis receives scientific advice from EMA on voreloxin program
Read More